Literature DB >> 7977290

Use of diuretics and other antihypertensive medications in relation to the risk of renal cell cancer.

S Weinmann1, A G Glass, N S Weiss, B M Psaty, D S Siscovick, E White.   

Abstract

In a population-based case-control study of the association between use of diuretics and renal cell cancer, 120 white men whose cancer was diagnosed during the years 1980-1991 and 86 white women diagnosed in 1960-1991 were identified among members of the Kaiser Permanente Northwest health plan. Controls were plan members who had been individually matched to cases on sex, race, age, and time period in the plan. Data on diuretic use and other selected variables were abstracted from outpatient and inpatient medical records. In an analysis confined to exposures present at least 2 years before case diagnosis, the odds ratios associated with any use of a diuretic drug were 2.2 (95% confidence interval 1.2-3.9) for men and 1.8 (95% confidence interval 1.01-3.2) for women. Increased duration of diuretic use was associated with an increased risk of renal cell cancer. This association was not restricted to one class of diuretic and was not confounded by cigarette smoking or body mass. Both hypertension and use of nondiuretic antihypertensive drugs were closely associated with diuretic use, and it was impossible to disentangle fully the effects of these three separate exposures. These results, together with those of prior studies, are generally compatible with the view that there is an association between diuretic use and the incidence of renal cell cancer, but the interpretation of that association remains in question.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7977290     DOI: 10.1093/oxfordjournals.aje.a117328

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  14 in total

1.  Hypertension and risk of renal cell carcinoma among white and black Americans.

Authors:  Joanne S Colt; Kendra Schwartz; Barry I Graubard; Faith Davis; Julie Ruterbusch; Ralph DiGaetano; Mark Purdue; Nathaniel Rothman; Sholom Wacholder; Wong-Ho Chow
Journal:  Epidemiology       Date:  2011-11       Impact factor: 4.822

Review 2.  Carcinogenicity of antihypertensive therapy.

Authors:  Ehud Grossman; Franz H Messerli; Uri Goldbourt
Journal:  Curr Hypertens Rep       Date:  2002-06       Impact factor: 5.369

Review 3.  Carcinogenicity of cardiovascular drugs.

Authors:  E Grossman; F H Messerli; U Goldbourt
Journal:  Curr Hypertens Rep       Date:  1999-06       Impact factor: 5.369

4.  Antihypertensive medication use and risk of renal cell carcinoma.

Authors:  Joanne S Colt; Jonathan N Hofmann; Kendra Schwartz; Wong-Ho Chow; Barry I Graubard; Faith Davis; Julie Ruterbusch; Sonja Berndt; Mark P Purdue
Journal:  Cancer Causes Control       Date:  2017-02-21       Impact factor: 2.506

5.  Angiotensin receptor blockers, cancer, and smoking.

Authors:  Iñaki Marina; Lawrence R Krakoff
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-12       Impact factor: 3.738

Review 6.  Antihypertensive therapy and cancer risk.

Authors:  D C Felmeden; G Y Lip
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

7.  Epidemiologic characteristics and risk factors for renal cell cancer.

Authors:  Loren Lipworth; Robert E Tarone; Lars Lund; Joseph K McLaughlin
Journal:  Clin Epidemiol       Date:  2009-08-09       Impact factor: 4.790

Review 8.  Nonhormonal drugs and cancer.

Authors:  P D Stolley; S H Zahm
Journal:  Environ Health Perspect       Date:  1995-11       Impact factor: 9.031

9.  Hypertension, obesity and their medications in relation to renal cell carcinoma.

Authors:  J M Yuan; J E Castelao; M Gago-Dominguez; R K Ross; M C Yu
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

10.  Meat intake, 'mate' drinking and renal cell cancer in Uruguay: a case-control study.

Authors:  E De Stefani; L Fierro; M Mendilaharsu; A Ronco; M T Larrinaga; J C Balbi; S Alonso; H Deneo-Pellegrini
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.